Literature DB >> 25791047

[Automobile driving capacity in dementia].

Rolf Seeger1.   

Abstract

Dementia influences at an early stage the driving aptitude of motor vehicle steering persons. Every year in Switzerland, around 16'000 driving permit holders suffer newly from dementia; therefore the driving aptitude is questioned, especially because of possibly limited executive functions. Individuals with early-stage dementia often may show a dangerous driving stile. However, a mild dementia does not a priori exclude the driving aptitude, and less than half of these drivers can continue driving for another 1 - 3 years. In contrast, there is no further driving aptitude in presence of moderate dementia. In the assessment of driving aptitude, the underlying cause of dementia is always taken into account. Cognitive short tests such as the Mini-Mental Status Exam, Clock Drawing Test and Trail-Making Test are not suitable to make reliable statements about the aptitude to drive, but these tests are very important for the initial diagnosis of dementia in primary care practice and can lead the way for further examination concerning driving aptitude. The legally prescribed regular check-up for motorists aged over 70 years in Switzerland provides an ideal opportunity for early detection of incipient dementia. The practical procedure for the assessment of aptitude to drive in the primary care practice is presented. The physician-guided on-road driving test represents a meaningful, practical and relatively cost-effective tool for the evaluation of driving aptitude in cases of doubt.

Entities:  

Mesh:

Year:  2015        PMID: 25791047     DOI: 10.1024/0040-5930/a000671

Source DB:  PubMed          Journal:  Ther Umsch        ISSN: 0040-5930


  1 in total

1.  Strong evidence for age as the single most dominant predictor of medically supervised driving test-mini mental status test outcomes provide only weak but significant moderate additional predictive value.

Authors:  Yannik Isler; Simon Schwab; Regula Wick; Stefan Lakämper
Journal:  BMC Geriatr       Date:  2022-03-24       Impact factor: 3.921

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.